 |
Vol.58 No.3 contents | Japanese/English |
 | Full Text of PDF (1484K) Article in Japanese |
- Invited Review Article -
Current Status and Issues of PD-L1 Testing in Non-small Cell Lung Cancer
Genichiro Ishii11Division of Pathology, Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Japan
Unlike anti-cancer drugs and molecular-targeted drugs that directly act on cancer cells, immune checkpoint inhibitors (anti-PD-1/PD-L1 antibodies) exert their effects by modifying the immune microenvironment of cancer. Several antibodies are currently in advanced clinical trials or have gained regulatory approval; however, different companion diagnostic agents have been developed for each drug. PD-L1 immunostaining (PD-L1 IHC) is a biomarker assay for anti-PD-1/PD-L1 antibodies, but the detailed diagnostic criteria are poorly recognized. Furthermore, new problems associated with the actual PD-L1 IHC judgment have been highlighted. Even if a standard operating procedure document is prepared, the above problems will probably not be resolved. In this paper, we will describe and discuss the current state, issues and future countermeasures associated with PD-L1 IHC.
key words: Immune checkpoint inhibitor, Programmed cell death protein 1 (PD-1), Programmed death-ligand 1 (PD-L1), Tumor proportion score (TPS), Immunohistochemistry (IHC)
JJLC 58 (3): 189-195, 2018
